143 related articles for article (PubMed ID: 24288046)
1. Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.
Sengler C; Niewerth M; Kallinich T; Nimtz-Talaska A; Haller M; Huppertz HI; Minden K
Clin Rheumatol; 2014 Jan; 33(1):137-9. PubMed ID: 24288046
[TBL] [Abstract][Full Text] [Related]
2. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
[TBL] [Abstract][Full Text] [Related]
3. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.
Nolan T; Roy-Ghanta S; Montellano M; Weckx L; Ulloa-Gutierrez R; Lazcano-Ponce E; Kerdpanich A; Safadi MA; Cruz-Valdez A; Litao S; Lim FS; de Los Santos AM; Weber MA; Tinoco JC; Mezerville MH; Faingezicht I; Kosuwon P; Lopez P; Borja-Tabora C; Li P; Durviaux S; Fries L; Dubin G; Breuer T; Innis BL; Vaughn DW
J Infect Dis; 2014 Aug; 210(4):545-57. PubMed ID: 24652494
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
5. Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign.
Touma Z; Gladman DD; Urowitz MB
Curr Opin Rheumatol; 2013 Mar; 25(2):164-70. PubMed ID: 23370371
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
[TBL] [Abstract][Full Text] [Related]
7. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM
Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447
[TBL] [Abstract][Full Text] [Related]
8. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
[TBL] [Abstract][Full Text] [Related]
9. Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.
Vaughn DW; Seifert H; Hepburn A; Dewe W; Li P; Drame M; Cohet C; Innis BL; Fries LF
Hum Vaccin Immunother; 2014; 10(10):2942-57. PubMed ID: 25483467
[TBL] [Abstract][Full Text] [Related]
10. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
[TBL] [Abstract][Full Text] [Related]
11. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
[TBL] [Abstract][Full Text] [Related]
12. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.
McElhaney JE; Beran J; Devaster JM; Esen M; Launay O; Leroux-Roels G; Ruiz-Palacios GM; van Essen GA; Caplanusi A; Claeys C; Durand C; Duval X; El Idrissi M; Falsey AR; Feldman G; Frey SE; Galtier F; Hwang SJ; Innis BL; Kovac M; Kremsner P; McNeil S; Nowakowski A; Richardus JH; Trofa A; Oostvogels L;
Lancet Infect Dis; 2013 Jun; 13(6):485-96. PubMed ID: 23518156
[TBL] [Abstract][Full Text] [Related]
13. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.
Launay O; Duval X; Fitoussi S; Jilg W; Kerdpanich A; Montellano M; Schwarz TF; Watanveerade V; Wenzel JJ; Zalcman G; Bambure V; Li P; Caplanusi A; Madan A; Gillard P; Vaughn DW
BMC Infect Dis; 2013 Sep; 13():435. PubMed ID: 24041010
[TBL] [Abstract][Full Text] [Related]
14. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
Ahmed SS; Schur PH; MacDonald NE; Steinman L
J Autoimmun; 2014 May; 50():1-11. PubMed ID: 24559657
[TBL] [Abstract][Full Text] [Related]
15. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents.
Garcia-Sicilia J; Gillard P; Carmona A; Tejedor JC; Aristegui J; Merino JM; Behre U; Caplanusi A; Vaman T; Dieussaert I
Vaccine; 2011 Jun; 29(26):4353-61. PubMed ID: 21504774
[TBL] [Abstract][Full Text] [Related]
19. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
Garcia-Sicilia J; Arístegui J; Omeñaca F; Carmona A; Tejedor JC; Merino JM; García-Corbeira P; Walravens K; Bambure V; Moris P; Caplanusi A; Gillard P; Dieussaert I
Hum Vaccin Immunother; 2015; 11(10):2359-69. PubMed ID: 26176592
[TBL] [Abstract][Full Text] [Related]
20. HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children.
Leahy TR; Goode M; Lynam P; Gavin PJ; Butler KM
Influenza Other Respir Viruses; 2014 May; 8(3):360-6. PubMed ID: 24548473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
